Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Gross Margin (2023 - 2025)

Bioregenx's Gross Margin history spans 3 years, with the latest figure at 82.66% for Q4 2025.

  • Quarterly results put Gross Margin at 82.66% for Q4 2025, up 1258.0% from a year ago — trailing twelve months through Dec 2025 was 81.08% (up 1021.0% YoY), and the annual figure for FY2025 was 81.08%, up 1021.0%.
  • Gross Margin for Q4 2025 was 82.66% at Bioregenx, down from 83.98% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 83.98% in Q3 2025 to a low of 55.76% in Q4 2023.
  • The 3-year median for Gross Margin is 71.46% (2023), against an average of 72.98%.
  • The sharpest move saw Gross Margin plummeted -376bps in 2024, then surged 1502bps in 2025.
  • Year by year, Gross Margin stood at 55.76% in 2023, then rose by 26bps to 70.09% in 2024, then rose by 18bps to 82.66% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 82.66%, 83.98%, and 79.03% for Q4 2025, Q3 2025, and Q2 2025 respectively.